Arrowhead Pharmaceuticals (NASDAQ:ARWR) Posts Earnings Results, Misses Expectations By $0.65 EPS

Arrowhead Pharmaceuticals (NASDAQ:ARWR) posted its earnings results on Monday. The biotechnology company reported ($0.61) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.04 by ($0.65), MarketWatch Earnings reports. Arrowhead Pharmaceuticals had a negative return on equity of 28.00% and a negative net margin of 116.97%. During the same quarter last year, the business posted ($0.48) earnings per share.

ARWR traded up $0.36 on Wednesday, hitting $71.25. The company’s stock had a trading volume of 1,609 shares, compared to its average volume of 742,274. The company’s 50 day simple moving average is $66.91 and its 200-day simple moving average is $69.40. The firm has a market cap of $7.43 billion, a P/E ratio of -57.63 and a beta of 1.14. Arrowhead Pharmaceuticals has a 12 month low of $56.05 and a 12 month high of $93.66.

In other news, Director Adeoye Y. Olukotun sold 5,000 shares of the firm’s stock in a transaction on Monday, September 13th. The shares were sold at an average price of $63.76, for a total transaction of $318,800.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Martin Javier San sold 19,500 shares of the firm’s stock in a transaction on Friday, November 19th. The shares were sold at an average price of $69.31, for a total transaction of $1,351,545.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 89,500 shares of company stock valued at $5,945,295. 3.50% of the stock is owned by insiders.

An institutional investor recently raised its position in Arrowhead Pharmaceuticals stock. LPL Financial LLC grew its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 100.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 19,116 shares of the biotechnology company’s stock after buying an additional 9,579 shares during the quarter. LPL Financial LLC’s holdings in Arrowhead Pharmaceuticals were worth $1,193,000 at the end of the most recent quarter. Institutional investors and hedge funds own 63.54% of the company’s stock.

A number of equities research analysts have issued reports on the stock. SVB Leerink upped their price objective on shares of Arrowhead Pharmaceuticals from $44.00 to $45.00 and gave the stock a “market perform” rating in a research report on Tuesday. Chardan Capital reduced their price objective on shares of Arrowhead Pharmaceuticals from $97.00 to $94.00 and set a “buy” rating for the company in a research report on Friday, August 6th. TheStreet raised shares of Arrowhead Pharmaceuticals from a “d+” rating to a “c-” rating in a research report on Thursday, November 4th. Finally, HC Wainwright increased their target price on shares of Arrowhead Pharmaceuticals from $95.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, August 10th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $88.09.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R.

Featured Article: What is the CAC 40 Index

Earnings History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.